Asano N,Ishii S,Kizu H, et al (2000) In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem
Azen C,Koch R,Friedman E,Wenz E,Fishler K (1996) Summary of findings from the United States Collaborative Study of children treated for phenylketonuria. Eur J Pediatr
155(supplement 1): S29–32.
Barranger JA,Rice EO,Dunigan J, et al (1997) Gaucher's disease: studies of gene transfer to haematopoietic cells. Baillières Clin Haematol
Barton NW,Furbish FS,Murray GJ,Garfield M,Brady RO (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA
Barton NW,Brady RO,Dambrosia JM, et al (1991) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med
Baudhuin P,Hers HG,Loeb H (1964) An electron microscopic and biochemical study of type II glycogenosis. Lab Invest
Beutler E,Westwood B,Dale GL (1983) The effect of phlebotomy as a treatment of Fabry disease. Biochem Med
Bijvoet AG,Van Hirtum H,Kroos MA, et al (1999) Human acid α-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet
Bishop DF,Kovac CR,Desnick RJ (1981) Enzyme therapy XX: further evidence for the differential in vivo fate of human splenic and plasma forms of a-galactosidase A in Fabry disease. Recovery of exogenous activity from hepatic tissue. In Callahan JW,Lowden JA, eds. Lysosomes and Lysosomal Storage Diseases. New York: Raven Press, 381–394.
Bishop DF,Calhoun DH,Bernstein HS,Hantzopoulos P,Quinn M,Desnick RJ (1986) Human α-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci USA
Brady RO,Barton NW (1991) Enzyme replacement therapy for type I Gaucher disease. In Desnick RJ, ed. Treatment of Genetic Diseases. New York: Churchill Livingstone, 153–168.
Brady RO,Tallman JF,Johnson WG, et al (1973) Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med
Brady RO,Pentchev PG,Gal AE,Hibbert SR,Dekaban AS (1974) Replacement therapy for inherited enzyme deficiency: use of purified glucocerebrosidase in Gaucher's disease. N Engl J Med
Cox T,Lachmann R,Hollak C, et al (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet
DCCT (1993) The effect of intensive treatment of diabetes on the development and pro-gression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med
de Duve C (1959). In Hayashi T, ed. Subcellular Particles. New York: Ronald Press, 128–159.
de Duve C (1964) From cytases to lysosomes. Fed Proc
de Duve C (1975) Exploring cells with a centrifuge. Science 189: 186–194.
de Duve C (1983) Lysosomes revisited. Eur J Biochem
de Duve C,Wattiaux R (1966) Functions of lysosomes. Annu Rev Physiol
de Duve C,Pressman BC,Gianetto R,Wattiaux R,Appelmans F (1955) Tissue fractionation. 6. Intracellular distribution patterns of enzymes in rat-liver tissues. Biochem J
Desnick RJ (ed.) (1980) Enzyme Therapy in Genetic Diseases: 2. New York: Alan R. Liss.
Desnick RJ,Fiddler MB (1976) Advances in the treatment of genetic diseases: an overview. In: Kelly S, ed. Birth Defects: Risks and Consequences. New York: Academic Press, 329–356.
Desnick RJ,Bernlohr RW,Krivit W (eds) (1973) Enzyme Therapy in Genetic Diseases, Birth Defects. Original Article Series, Vol. IX. Baltimore: Williams & Wilkins.
Desnick RJ,Dean KJ,Grabowski G,Bishop DF,Sweeley CC (1979) Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic a-galactosidase A isozymes. Proc Natl Acad Sci USA
Desnick RJ,Dean KJ,Grabowski GA,Bishop DF,Sweeley CC (1980) Enzyme therapy XVII: metabolic and immunologic evaluation of α-galactosidase A replacement in Fabry disease. In: Desnick RJ, ed. Enzyme Therapy in Genetic Diseases: 2. New York: Alan R. Liss, 393–413.
Desnick RJ,Ioannou YA,Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In Scriver CR,Beaudet AL,Sly WS,Valle D,Childs B,Kinzler KE,Vogelstein B, eds. TheMetabolic andMolecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3733–3774.
Dingle JT,Fell HB (eds) (1969) Lysosomes in Biology and Pathology. Amsterdam: North-American.
Dunbar CE,Kohn DB,Schi¡mann R, et al (1998) Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detec-tion of transduced cells without myeloablation. Hum Gene Ther
Eng CM,Cochat P,Wilcox WR, et al (2000a) Enzyme replacement therapy in Fabry disease: results of a placebo-controlled phase 3 trial. Am J Hum Genet
67(supplement 2): 38.
Eng CM,Phelps R,Kim L, et al (2000b) Enzyme replacement therapy in Fabry diseases: results of a phase I/II clinical trial. J Inherit Metab Dis
Eng CM,Banikazemi M,Gordon R, et al (2001a) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Human Genet
Eng CM,Guffon N,Wilcox WR, et al (2001b) A multicenter, randomized, double-blind, placebo-controlled study of the safety and e¤cacy of recombinant human a-galactosidase A replacement therapy in Fabry disease. N Engl J Med (submitted).
Fan JQ,Ishii S,Asano N,Suzuki Y (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nature Medicine
Fleischer LD,Gaull GE (1980) Enzyme manipulation by specific megavitamin therapy. In Desnick RJ, ed. Enzyme Therapy in Genetic Diseases: 2. New York: Alan R. Liss, 239–268.
Gamper HB,Parekh H,Rice MC,Bruner M,Youkey H,Kmiec EB (2000) TheDNAstrand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts. Nucleic Acids Res
Grabowski GA,Barton NW,Pastores G, et al (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med
Grabowski GA,Leslie N,Wenstrup R (1998) Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev
Hers HG (1963) α-Glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease). Biochem J
Hers HG,Van Hoof F (eds) (1973) Lysosomes and Storage Diseases. New York: Academic Press.
Holtzman E (eds) (1989) Lysosomes. New York: Plenum Press.
Ioannou YA,Bishop DF,Desnick RJ (1992) Overexpression of human α-galactosidase A results in its intracellular aggregation, crystallization in lysosomes and selective secretion. J Cell Biol
Ioannou YA,Zeidner KM,Gordon RE,Desnick RJ (2001) Fabry disease: preclinical studies demonstrate the eFFectiveness of α-galactosidase A replacement in enzyme-de¢cient mice. Am J Hum Genet
Johnson WG,Desnick RJ,Long DM, et al (1973) Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease. In Desnick RJ,Bernlohr RW,Krivit W, eds. Enzyme Therapy in Genetic Diseases, Birth Defects. Original Article Series, vol. IX, no. 2. Baltimore: Williams & Wilkins, 120124.
Kakkis ED,McEntee MF,Schmidtchen A, et al (1996) Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med
Kakkis E,Muenzer J,Tiller G, et al (2001) Enzyme replacement therapy in mucopoly-saccharidosis I. N Engl J Med
Kikuchi T,Yang HW,Pennybacker M, et al (1998) Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail. JClin Invest
Kolodny EH,Ullman MD,Pyeritz RE,Moser HW (1981) Plasmapheresis therapy for the lipidoses. In Callahan JW,Lowden JA, eds. Lysosomes and Lysosomal Storage Diseases. New York: Raven Press, 395–403.
Levy HL (1991) Nutritional therapy in inborn errors of metabolism. In Desnick RJ, ed. Treat-ment of Genetic Diseases. New York: Churchill Livingstone.
Maizel SE,Simmons RL,Kjellstrand C,Fryd DS (1981) Ten-year experience in renal trans-plantation for Fabry's disease. Transplant Proc
Mapes CA,Anderson RL,Desnick RJ,Krivit W,Sweeley CC (1970) Enzyme replacement as a possible therapy for Fabry's disease. Science
Miranda SR,He X,Simonaro CM, et al (2000) Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J
Mistry PK (1999) Gaucher's disease: a model for modern management of a genetic disease. J Hepatol
Okumiya T,Ishii S,Takenaka T, et al (1995) Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Biochem Biophys Res Commun
Platt FM,Butters TD (1998) New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem Pharmacol
Platt FM,Jeyakumar M,Andersson U,Priestman DA,Dwek RA,Butters TA (2001) Inhibition of substrate synthesis as a strategy for glycolipid liposomal storage disease therapy. J Inherit Metab Dis
Rattazzi MC,Dobrrenis K (1991) Enzyme replacement: overview and prospects. In Desnick RJ, ed. Treatment of Genetic Diseases. New York: Churchill Livingstone, 131–152.
Schiffmann R,Kopp JB,Austin H, et al (2000) Eficacy and safety of enzyme replacement therapy for Fabry disease demonstrated by a double-blind placebo-controlled trial. Am J Hum Genet
67(supplement 2): 38.
Scriver CR,Beaudet AL,Sly WS,Valle D,Childs B,Kinzler KE,Vogelstein B (eds) (2001) The Metabolic and Molecular Bases of Inherited Diseases, 8th edn. New York: McGraw-Hill.
Tager JM,Hooghvinkel GJM,Daems WT (eds) (1974) Enzyme Therapy in Lysosomal Storage Diseases. Amsterdam: North-Holland.
Turner CT,Hopwood JJ,Brooks DA (2000) Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of α-L-iduronidase in immunized rats. Mol Genet Metab
van den Hout H,Reuser A,Vulto A, et al (2000) First clinical test with recombinant human α-glucosidase from rabbit milk shows therapeutic e¡ect in Pompe disease. Am J Hum Genet
67(supplement 2): 6.
Wang AM,Ioannou YA,Zeidner KM, et al (1996) Generation of a mouse model with α-galactosidase A deficiency. Am J Hum Genet
Welch WJ,Brown CR (1996) In£uence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones
Ziegler RJ,Yew NS,Li C, et al (1999) Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum Gene Ther